HCV Treatment
HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016
... high treatment success rates, few side effects, and short treatment regimens (8– 12 weeks), began to offer new hope that public health of- ficials and clinical experts could begin to curb the HCV ...
9
Economic study of the value of expanding HCV treatment capacity in Germany
... of HCV transmission and progression was constructed, incorporating nationally representative data on HCV prevalence, incidence and progression; mortality, treatment costs, medical expenditures, ...
9
HIV Prevalence among HCV Egyptian Infected Patients and Its Impact on the Result of HCV Treatment
... Study: HCV infection is the most common co-infection in HIV patients so we aimed to determine the prevalence of HIV infection in chronic HCV patients and its impact on chronic HCV patients ...
7
Rapid and large scale implementation of HCV treatment advances in France, 2007–2015
... initiating HCV treatment over the studied period may be the re- sult of a combination of the following factors: the avail- ability of the successive new therapies, the evolution of the knowledge on DAAs ...
12
Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs
... for HCV care by providing screening and services at locations that are convenient to PWID, in- cluding methadone clinics, drug treatment programs, detoxification centers [33–35], mobile medical clinics [30, ...
10
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co infected patients, Cohere in Eurocoord
... DOC 29 kb Abbreviations HCV: Hepatitis C virus; cART: combination antiretroviral therapy; Cohere: Collaboration of Observational HIV Epidemiological Research in Europe; SVR: Sustained vi[r] ...
10
Hepatitis C treatment initiation in HIV HCV coinfected patients
... HIV treatment centers [23]. All HIV/HCV coinfected patients enrolled in the cohort between 2000 and 2012 were ...[23]. HCV infection was defined as a positive HCV serology, and/or a detectable ...
9
Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross sectional study
... compare treatment rates in patients with mono- infection ...for HCV care to infectious diseases/HIV and hepatology ...for HCV care to spe- cialty clinics, it is not surprising that the overall ...
10
Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance
... 1 HCV (subtyping not performed) after present- ing with ...confirmed HCV RNA at 191,514 ...initiating HCV treatment, surveillance AFP levels rose from 37 to 434 ...protocol, HCV therapy ...
5
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV HCV co infected patients
... preclude HCV treatment such that providers may make subjective and possibly inappropriate decisions to withhold HCV therapies in these ...HIV treatment care centers ...
9
The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception
... of treatment uptake, HCV providers may choose to spend some time exploring disease representa- tions in this group both before and during HCV treat- ...with HCV likely have clear illness ...
8
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review
... of HCV treatment may also hamper uptake and adherence, although new medication increases the efficacy of ...standard treatment for chronic HCV infection is a combination of pegylated ...
9
Complexity and Catalytic Efficiency of Hepatitis C Virus (HCV) NS3 and NS4A Protease Quasispecies Influence Responsiveness to Treatment with Pegylated Interferon plus Ribavirin in HCV/HIV-Coinfected Patients
... the HCV treatment response, we analyzed the pretreatment NS3/4A protease gene quasispecies composition of 56 HCV genotype 1–HIV-1-coinfected patients treated in our clinic with pegylated IFN (pegIFN) ...
9
Finally sofosbuvir: an oral anti-HCV drug with wide performance capability
... reduced treatment durations, and few, if any, dosing restrictions recognized to ...of HCV-positive individuals, yet a simple and far more tolerable oral drug is now available to greatly expand the ...
12
The role of HCV proteins on treatment outcomes
... IFN treatment was investigated by different groups in Japan, Europe and the United ...and treatment response [114, ...to HCV treatment responsiveness ...to treatment [107, 134, ...in ...
12
Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection
... 1) HCV PA completion; 2) HCV medication adherence counseling; 3) HCV DDI counseling and screening; 4) HCV medication counseling regarding common AEs; 5) HCV counseling regarding ...
7
Eliminating suffering through the birth of metta : a critical hermeneutic inquiry of the identity and ethical intention of selected monks of Burma
... There are several limitations of this study. Fibrosis progression scores are based on a liver biopsy test, both of which are dependent on the skills and expertise of the individual pathologist. The dependence of the ...
97
Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015
... addiction treatment [31] was required to initiate HCV ...with HCV genotype 1b or with HIV infection were treated for 48 weeks, and those with genotypes 2 or 3 were treated for 24 weeks ...Individual ...
7
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality
... This analysis focused on chronically infected individuals. Once a patient achieved SVR they were removed from the infected cohort. Although studies have shown that patients with SVR retain some risk of HCC, ...
10
Arsenic Trioxide Inhibits Hepatitis C Virus RNA Replication through Modulation of the Glutathione Redox System and Oxidative Stress
... inhibit HCV RNA replication, suggesting that STAT3 positively reg- ulates HCV replication ...ATO treatment on a set of stress-signaling events, including the NF- B, AP-1, and STAT3 pathways, since ...
11